Ischemia-modified albumin levels in patients with idiopathic sudden sensorineural hearing loss

Yıl 2019, Cilt: 29 Sayı: 1, 21 - 27, 10.03.2019

Ahmet Adnan Cırık Muhammed Fatih Evcimik Gözde Ülfer Türkan Yiğitbaşı Öztürk Aktaş

Öz

Objectives: This study aims to investigate whether serum levels of ischemia-modified albumin IMA are associated with idiopathic sudden sensorineural hearing loss ISSNHL . Patients and Methods: Between December 2015 and June 2017, a total of 17 patients 9 males, 8 females; mean age 49.4±18.0 years; range, 24 to 88 years with ISSNHL and 24 age- and sex-matched healthy individuals 12 males, 12 females; mean age 44.5±13.3 years; range, 30 to 81 years as the control group were included in the study. All patients underwent audiometric examination at the time of admission immediately before the beginning of the treatment and weekly after treatment initiation until one month using the Interacoustics AC40 audiometer. Serum IMA levels were evaluated using blood samples from the antecubital vein of both patient and control groups. The samples were centrifuged to separate the serum from the cells. Albumin cobalt binding test was used for IMA measurement. Results: The mean IMA level was 0.374±0.081 absorbance units ABSU range, 0.205 to 0.536 in the study group at the time of diagnosis, 0.358±0.051 ABSU range, 0.297 to 0.466 in the post-treatment period, at least four weeks after onset, and 0.358±0.053 ABSU range, 0.281 to 0.434 in the control group. There was no statistically significant difference between the patient and control groups. The IMA levels of the patients with ISSNHL in the post-treatment period were lower than the onset of illness, although this difference was not statically significant 0.440 . Conclusion: Our study results demonstrated that serum IMA levels in the patients with ISSNHL did not differ from the control group.

Anahtar Kelimeler

Ischemia-modified albumin, idiopathic sudden sensorineural hearing loss

Kaynakça

• Chau JK, Lin JR, Atashband S, Irvine RA, Westerberg BD. Systematic review of the evidence for the etiology of adult sudden sensorineural hearing loss. Laryngoscope 2010;120:1011-21.
• Alexander TH, Harris JP. Incidence of sudden sensorineural hearing loss. Otol Neurotol 2013;34:1586-9.
• Byl FM Jr. Sudden hearing loss: eight years' experience and suggested prognostic table. Laryngoscope 1984;94:647-61.
• Hughes GB, Freedman MA, Haberkamp TJ, Guay ME. Sudden sensorineural hearing loss. Otolaryngol Clin North Am 1996;29:393-405.
• Lautermann J, Sudhoff H, Junker R. Transtympanic corticoid therapy for acute profound hearing loss. Eur Arch Otorhinolaryngol 2005;262:587-91.
• Capaccio P, Ottaviani F, Cuccarini V, Bottero A, Schindler A, Cesana BM, et al. Genetic and acquired prothrombotic risk factors and sudden hearing loss. Laryngoscope 2007;117:547-51.
• Einer H, Tengborn L, Axelsson A, Edström S. Sudden sensorineural hearing loss and hemostatic mechanisms. Arch Otolaryngol Head Neck Surg 1994;120:536-40.
• Lin C, Lin SW, Lin YS, Weng SF, Lee TM. Sudden sensorineural hearing loss is correlated with an increased risk of acute myocardial infarction: a population-based cohort study. Laryngoscope 2013;123:2254-8.
• Lin HC, Chao PZ, Lee HC. Sudden sensorineural hearing loss increases the risk of stroke: a 5-year follow-up study. Stroke 2008;39:2744-8.
• Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006;92:113-4.
• Bar-Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 2001;268:42-7.
• Chan B, Dodsworth N, Woodrow J, Tucker A, Harris R. Site-specific N-terminal auto-degradation of human serum albumin. Eur J Biochem 1995;227:524-8.
• Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt- albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000;19:311-5.
• Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med 2011;49:177-84.
• Sari K, Gencer ZK, Ede H, Gocmen AY, Kantekin Y. Ischemia-modified albumin, brain natriuretic peptide, and growth differentiation factor-15 levels in patients with nasal polyps. Auris Nasus Larynx 2016;43:529-36.
• Sunnetcioglu A, Asker S, Alp HH, Gunbatar H. Increased Asymmetric Dimethylarginine and Ischemia-Modified Albumin Levels in Obstructive Sleep Apnea. Respir Care 2016;61:1038-43.
• Rudack C, Langer C, Stoll W, Rust S, Walter M. Vascular risk factors in sudden hearing loss. Thromb Haemost 2006;95:454-61.
• Suckfüll M, Wimmer C, Reichel O, Mees K, Schorn K. Hyperfibrinogenemia as a risk factor for sudden hearing loss. Otol Neurotol 2002;23:309-11.
• Park YA, Kong TH, Seo YJ. A sustained increase of plasma fibrinogen in sudden sensorineural hearing loss predicts worse outcome independently. Am J Otolaryngol 2017;38:484-7.
• Lominadze D, Dean WL, Tyagi SC, Roberts AM. Mechanisms of fibrinogen-induced microvascular dysfunction during cardiovascular disease. Acta Physiol (Oxf) 2010;198:1-13.
• Capaccio P, Cuccarini V, Ottaviani F, Fracchiolla NS, Bossi A, Pignataro L. Prothrombotic gene mutations in patients with sudden sensorineural hearing loss and cardiovascular thrombotic disease. Ann Otol Rhinol Laryngol 2009;118:205-10.
• Gul F, Muderris T, Yalciner G, Sevil E, Bercin S, Ergin M, et al. A comprehensive study of oxidative stress in sudden hearing loss. Eur Arch Otorhinolaryngol 2017;274:1301-8.
• Göde S, Turhal G, Kaya İ, Mavili Hİ, Kirazlı T. Evaluation of Procalcitonin and hs-CRP Levels in Sudden Sensorineural Hearing Loss. J Int Adv Otol 2018;14:44-7.
• Kim C, Sohn JH, Jang MU, Hong SK, Lee JS, Kim HJ, et al. Ischemia as a potential etiologic factor in idiopathic unilateral sudden sensorineural hearing loss: Analysis of posterior circulation arteries. Hear Res 2016;331:144-51.
• Lippi G, Montagnana M. Ischemia-modified albumin in ischemic disorders. Ann Thorac Cardiovasc Surg 2009;15:137.
• Ataş H, Kocabıyık M, Gönül M, Öztürk Y, Kavutçu M. Usefulness of ischemia-modified albumin in predicting oxidative stress in patients with vitiligo. Biomark Med 2017;11:439-49.
• Ozdemir M, Kiyici A, Balevi A, Mevlitoğlu I, Peru C. Assessment of ischaemia-modified albumin level in patients with psoriasis. Clin Exp Dermatol 2012;37:610-4.
• Chandrashekar L, Kumarit GR, Rajappa M, Revathy G, Munisamy M, Thappa DM. 25-hydroxy vitamin D and ischaemia-modified albumin levels in psoriasis and their association with disease severity. Br J Biomed Sci 2015;72:56-60.
• Li J, Wang JS, Xie ZX, Wang WZ, Wang L, Ma GY, et al. Correlations among copeptin, ischemia-modified albumin, and the extent of myocardial injury in patients with acute carbon monoxide poisoning. Genet Mol Res 2015;14:10384-9.
• Ma SG, Yang LX, Bai F, Xu W, Hong B. Ischemia-modified albumin in patients with hyperthyroidism and hypothyroidism. Eur J Intern Med 2012;23:e136-40.
• Reddy SV, Suchitra MM, Pradeep V, Alok S, Suresh V, Bitla AR, et al. Ischemia-modified albumin levels in overt and subclinical hypothyroidism. J Endocrinol Invest 2015;38:885-90.
• Ersoy K, Anaforoğlu İ, Algün E. Serum ischemic modified albumin levels might not be a marker of oxidative stress in patients with hypothyroidism. Endocrine 2013;43:430-3.
• Xu Q, Du J, Ling X, Lu Y. Evaluation of MIh Scoring System in Diagnosis of Obstructive Sleep Apnea Syndrome. Med Sci Monit 2017;23:4715-22.
• Erkut N, Mentese A, Ozbas HM, Sumer A, Orem A, Topbas M, et al. The indicator of hypoxia in acute leukemia: Ischemia-modified albumin. Cancer Biomark 2015;15:559-65.